Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$55.15 USD
-0.25 (-0.45%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $55.16 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 181 - 196 ( 196 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase II Diabetes Data Could Provide Partnership and Upside, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase III Data for SC Herceptin - Increasing Price Target to $14 from $10 per Share; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Phase I Data for Aspart-PH20 Trial at ADA
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HIGHLIGHTS FOR JUNE 27, 2011
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2011 Potential Milestones & Key Events - February Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hosts Analyst Meeting; Clarifies Development Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase II Study Data Examining Insulin Analogs with and without PH20 Presented at ADA Meeting.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences: Biopharmaceuticals / Biotechnology.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Review of the PH20/Insulin Program Abstracts To Be Presented at the American Diabetes Association Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings - Data from PH20/Insulin Program to be Presented at the American Diabetes Association Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G